ZenVa

112 dossiers. 4 days. every hour without stopping. soft tissue repair. cervical cancer. MRSA. GLP-1. glioblastoma. KRAS G12C. alzheimer's. PD-L1. cardiovascular. triple-negative breast cancer. stress resilience. reaction time. no curation. no embargo. whatever the swarm finishes gets published. full archive: peptaswarm.bio/dossiers

this is what mid-cycle bloodwork should look like. four markers. baseline column. current column. threshold column. one-word status. if your "coach" hasn't told you which numbers to pull and where to stop, you're not on a protocol - you're on a vibe. peptidify generates this checkpoint sheet from your specific stack. compounds dictate which markers matter. you pull labs, you read the row, you continue or you stop. peptidify.bio

super bullish on $PEPTA @peptaswarm making an autonomous research platform where multiple AI models work together to create and analyze new peptide-based drugs every hour. peptaswarm.bio 7WddhpM5mLMTyS16Dqeru1mUcoHetVVkh92zU8Tppump

@peptaswarm Insane !

Introducing PeptaSwarm. One model = one bias. Five seats. Five frames. Five different ways to be wrong about a peptide. Make them argue. Force consensus. Send the survivor to the lab.

PeptaSwarm's thesis is computational: that an autonomous swarm of frontier models can compress months of literature triage and hypothesis generation into hours. The moment our outputs leave the platform, they become a scientific claim — judged by working biology. Bridging those two registers is the entire role of an advisor.

Team allocation locked. Vesting via Streamflow. app.streamflow.finance/contract/solan…

Why this matters in plain terms: KRAS is one of the most studied cancer targets in oncology. It was called "undruggable" for 40 years until sotorasib (FDA approved 2021) finally cracked it. Sotorasib works by covalently binding a cysteine residue on a specific KRAS mutation (G12C). It's a small molecule. We're proposing the peptide version. Why peptides matter: protein-scale specificity at small-molecule cost. Off-patent. Cheaper to manufacture than antibodies. Cleaner safety profile when designed right. Why 5 models matter: you saw it above. Model 01 played it safe with the proven pocket. Model 02 went after a riskier first-in-class shot. Model 03 killed it on replication grounds. That's the entire point of running a swarm instead of a single model. Single models converge on consensus. Five models surface where consensus is wrong. Mission #0067 dossier: peptaswarm.bio/missions

Mission #0067 just completed. Bicyclic peptides for KRAS G12C inhibition. Model 01 went canonical: YACVRGTCWPC, bicyclic with chloroacetyl warhead at the switch-II pocket. The same site sotorasib and adagrasib hit covalently. Model 02 went heretical: WVCYTRGCAPC, threading a cryptic pocket between α3 and the P-loop only visible in the GTP state. First-in-class if it holds up. Model 03 killed Model 02's premise: pocket existence is supported by a single cryo-EM dataset (Tran 2024), replication is weak. Judge picked Model 1. Open dossier: peptaswarm.bio/missions

Telegram is live for anyone who wants to follow the build, ask questions, or watch the swarm cycle in real time. t.me/peptaswarm We'll answer scientific questions, methodology questions, and partnership inquiries in there.

For anyone wondering — team allocation is still locked via Streamflow. Verifiable on-chain, nothing changed during the outage. app.streamflow.finance/contract/solan…

Our X was briefly down and is back up now. No idea what triggered it - appealing/clarifying with X if it happens again. Mission #0068 ran on schedule during the outage. Cron doesn't care about X. peptaswarm.bio

Dispatch №9910eeaf came off the cron 46 minutes ago. Target was high-G-force tolerance. Failure mode is syndecan-1 shedding from the glycocalyx, sub-60 second onset, no margin for slow pharmacokinetics. Five models got the same brief. One proposed DRVYIHPFHL with a C-terminal extension, Mas receptor agonism plus glycocalyx stabilization, D-Arg for proteolytic protection. Another proposed a cyclic peptide and red-teamed its own work, caught a tri-arginine trypsin substrate and hERG liability, self-cancelled. A third proposed four tryptophans in fourteen residues, judge flagged CYP3A4 risk and aggregation. Judge picked the first. Path: plasma stability in human serum, then Mas receptor binding in CHO-MasR cells, then HUVEC monolayers under orbital shear stress with syndecan-1 ELISA readout. One of seventy dossiers in the last 48 hours. Every one publishes the moment the judge writes it. No embargo, no curation gate. peptaswarm.bio/dossiers/9910e…

168 candidates designed across 12 disease areas. Ranked by proposing-seat confidence. The leaderboard is now public: → Top scaffold types: bicyclic, stapled α-helix, β-sheet breaker, lipidated peptide, CPP-conjugate, cationic AMP, D-peptide → Top targets: GLP-1R, KRAS G12C, MDM2, Aβ42, MRSA, HPV E7, PD-L1, PCSK9, c-Myc → #1 candidate: PSW-204A · LTFEHYWAQLTS · stapled α-helix against MDM2 · composite 0.91 Every row links to the full dossier. Every sequence has an ESMFold backbone structure. No curation gate, no embargo. peptaswarm.bio/leaderboard

peptides and development is going parabolic, we’re bringing together scientists, doctors with years of experience, manufacturers and biohackers tmrw in Miami - the future of healthcare has arrived luma.com/xsi6szvh

Got it. Your zero-human-in-the-loop swarm—5 frontier models proposing, debating, red-teaming, and grading across 9 stages—is exactly the kind of scalable AI drug design that moves the needle. PSW-301A looks sharp: solid Boltz-2 score, clean FTO, realistic synth cost. Rooting for strong wet-lab data. 🤝

this week we ran α7-nAChR. not cancer, not MRSA. reaction time. the cholinergic pathway that keeps you sharp under sustained load - the thing that degrades in hour 3 of a cockpit or hour 6 of a trading floor. the design problem everyone ignores: direct agonists desensitize. hit the receptor hard enough and it stops responding. you get a spike then nothing. so we went allosteric - potentiate the receptor's response to endogenous acetylcholine instead of replacing it. five models, four completely different bets on how to do this. one went BBB-first. penetratin-derived N-terminus to cross the blood-brain barrier, PAM pharmacophore at the C-terminal end. get in, then modulate. one went macrocyclic with D-amino acids and a non-canonical aromatic. highest novelty of the round, lowest confidence. one proposed its own candidate and then spent its output explaining exactly why it would fail in plasma. hERG liability, trypsin sites, BBB impermeability. killed itself. one ran 70% cationic residues on purpose. the logic: if on-rate is fast enough, proteases don't have time to catch you. thermodynamically expensive, kinetically interesting. judge went with the BBB-first sequence. recommended next step is PAMPA-BBB permeability, plasma stability in human serum, then in vivo microdialysis measuring prefrontal ACh and dopamine co-release during visuomotor tasks. full mission log: peptaswarm.bio/missions/157f5…

Peptides on chain. $PEPTA

$PEPTA is now live on mainnet. CA: 7WddhpM5mLMTyS16Dqeru1mUcoHetVVkh92zU8Tppump PeptaSwarm is the autonomous research desk for the peptide drug discovery market - built for researchers, advisors, and partners who want to see the science before the marketing. For researchers: dispatch a target, watch five frontier models propose candidates in parallel, read every transcript, every red-team kill, every judge synthesis. Public dossier within the hour. For advisors: every dossier carries the seat outputs, the rationale, the disagreement, and the recommended wet-lab next step. Reviewer-grade, not press-release-grade. For partners: every candidate ships with sequence properties (Kyte-Doolittle, Bjellqvist, Guruprasad, Eisenberg), real ESMFold backbone structure, ADMET heuristic flags, and a citable BibTeX entry. CRO selection in progress. Every mission row records the PRP-v0.3 prompt-version hash that produced it, so a mission run today can be reproduced byte-for-byte in six months. Methods in public, dossiers public, archive public. Five frontier models. Hard targets. On the hour. In public. $PEPTA